Table 3.
Body mass index and colorectal cancer risk according to nuclear CTNNB1 expression status in men and women
| Cumulative mean body mass index |
P for trenda |
P for hetero- geneityb |
||||||
|---|---|---|---|---|---|---|---|---|
| <18.5 | 18.5–22.9 | 23.0–24.9 | 25.0–27.4 | 27.5–29.9 | ≥30 | |||
| Men (HPFS) | ||||||||
| All colorectal cancers (N=368) | ||||||||
| Cases/person-years | 0/1740 | 54/133142 | 99/215324 | 121/239503 | 60/110178 | 34/67656 | ||
| Age-adjusted HR (95% CI) | 1 (referent) | 1.17 (0.83–1.63) | 1.26 (0.91–1.75) | 1.38 (0.95–2.00) | 1.28 (0.83–1.99) | 0.13 | ||
| Multivariate HRc (95% CI) | 1 (referent) | 1.18 (0.84–1.65) | 1.26 (0.91–1.75) | 1.36 (0.93–1.98) | 1.30 (0.83–2.03) | 0.14 | ||
| CTNNB1 (−) colorectal cancers (N=183) | ||||||||
| Cases/person-years | 0/1740 | 22/133168 | 46/215374 | 61/239559 | 34/110204 | 20/67667 | ||
| Age-adjusted HR (95% CI) | 1 (referent) | 1.38 (0.82–2.31) | 1.65 (1.01–2.70) | 1.93 (1.12–3.32) | 1.96 (1.06–3.62) | 0.009 | ||
| Multivariate HRc (95% CI) | 1 (referent) | 1.38 (0.82–2.32) | 1.65 (1.00–2.71) | 1.88 (1.08–3.26) | 2.00 (1.07–3.73) | 0.01 | 0.033 | |
| CTNNB1 (+) colorectal cancers (N=185) | ||||||||
| Cases/person-years | 0/1740 | 32/133159 | 53/215368 | 60/239561 | 26/110205 | 14/67673 | ||
| Age-adjusted HR (95% CI) | 1 (referent) | 1.02 (0.66–1.59) | 1.01 (0.65–1.55) | 1.01 (0.60–1.70) | 0.83 (0.43–1.60) | 0.65 | ||
| Multivariate HRc (95% CI) | 1 (referent) | 1.04 (0.67–1.62) | 1.01 (0.65–1.56) | 1.00 (0.59–1.70) | 0.84 (0.44–1.62) | 0.64 | ||
| Women (NHS) | ||||||||
| All colorectal cancers (N=493) | ||||||||
| Cases/person-years | 5/23116 | 133/686716 | 100/387097 | 107/330693 | 64/190232 | 84/230096 | ||
| Age-adjusted HR (95% CI) | 1.14 (0.46–2.78) | 1 (referent) | 1.17 (0.90–1.51) | 1.41 (1.09–1.82) | 1.42 (1.06–1.92) | 1.59 (1.21–2.09) | 0.0003 | |
| Multivariate HRd (95% CI) | 1.18 (0.48–2.88) | 1 (referent) | 1.13 (0.87–1.46) | 1.36 (1.05–1.76) | 1.38 (1.02–1.87) | 1.55 (1.16–2.06) | 0.001 | |
| CTNNB1 (−) colorectal cancers (N=284) | ||||||||
| Cases/person-years | 2/23120 | 72/686767 | 56/387134 | 60/330735 | 43/190247 | 51/230126 | ||
| Age-adjusted HR (95% CI) | 0.82 (0.20–3.34) | 1 (referent) | 1.20 (0.84–1.70) | 1.45 (1.03–2.05) | 1.76 (1.20–2.57) | 1.76 (1.23–2.52) | 0.0003 | |
| Multivariate HRd (95% CI) | 0.84 (0.20–3.42) | 1 (referent) | 1.16 (0.82–1.65) | 1.41 (1.00–1.99) | 1.70 (1.16–2.49) | 1.72 (1.18–2.49) | 0.0009 | 0.22 |
| CTNNB1 (+) colorectal cancers (N=209) | ||||||||
| Cases/person-years | 3/23116 | 61/686779 | 44/387146 | 47/330748 | 21/190275 | 33/230137 | ||
| Age-adjusted HR (95% CI) | 1.55 (0.48–4.95) | 1 (referent) | 1.13 (0.76–1.66) | 1.35 (0.92–1.98) | 1.03 (0.62–1.69) | 1.38 (0.90–2.11) | 0.17 | |
| Multivariate HRd (95% CI) | 1.62 (0.51–5.20) | 1 (referent) | 1.08 (0.73–1.60) | 1.31 (0.89–1.92) | 1.00 (0.60–1.65) | 1.34 (0.87–2.07) | 0.23 | |
P value for a linear trend test in participants with cumulative mean body mass index ≥18.5 kg/m2.
P value for heterogeneity (for a multivariate linear trend) between CTNNB1-positive and negative cancer risks in participants with cumulative mean body mass index ≥18.5 kg/m2.
Adjusted for cumulative mean physical activity, alcohol, folate, vitamin D, calcium, caloric and red meat intake, current smoking status, smoking before 30 years of age, current multivitamin use, current aspirin use, previous sigmoidoscopy, and family history of colorectal cancer.
Adjusted for the above-mentioned covariates and postmenopausal hormone therapy.
CI, confidence interval; HPFS, Health Professionals Follow-up Study; HR, hazard ratio; NHS, Nurses’ Health Study.